Svetomir N. Markovic

Author

Also Known As

, Markovic, Svetomir N., S Marković, S Markovič, S N Markovic, S. Markovic, S. N. Markovic, S.N. Markovic, S. N. Markovic, SVETOMIR N. MARKOVIC

592

Publications

17.8K

Citations

H-Index

140

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Arizona Mayo Clinic in Florida WinnMed Palmetto Hematology Oncology

About

Svetomir N. Markovic is an author at Mayo Clinic specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	98	4.8K
2	Health Sciences	18	23	1K
3	Public Health	5	5	650
4	Allergy	2	2	28
5	Engineering	1	1	28

Svetomir N. Markovic

213

Publications

12.6K

Citations

H-Index

Page 1

	Year	Citations
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials Edward L. Korn, Ping-Yu Liu, Sandra J. Lee, Journal of Clinical Oncology	2008	695
Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis Svetomir N. Markovic, Lori A. Erickson, Ravi D. Rao, Mayo Clinic Proceedings Part 1Cancer RiskCancer EpidemiologyMedicineEpidemiology Of Cancer	2007	367
Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies Justin Kao, Bing Liao, Svetomir N. Markovic, JAMA Neurology	2017	304
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma Luis F. Porrata, Morie A. Gertz, David J. Inwards, Blood	2001	266
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders Ryan A. Wilcox, Andrew L. Feldman, David A. Wada, Blood	2009	221
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma Kevin B. Kim, Jeffrey A. Sosman, John P. Fruehauf, Journal of Clinical Oncology	2011	196
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma Ryan A. Wilcox, Kay M. Ristow, Thomas M. Habermann, Leukemia Hematological MalignancyLymphoid NeoplasiaMedicinePrognosisImmunology	2011	186
Inhibition of Interferon Stimulation of Natural Killer Cell Activity in Mice Anesthetized with Halothane or Isoflurane Svetomir N. Markovic, Paul R. Knight, Donna M. Murasko Anesthesiology	1993	179
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu, European Journal of Cancer Anti-pd-1 TherapyMedicineMelanomaImmunologyPharmacology	2017	179
CX3CR1 identifies PD-1 therapy–responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy Yiyi Yan, Siyu Cao, Xin Liu, JCI Insight ImmunologyAbcb1 TransporterCd4 T Cell ResponsesImmune Cell TherapyImmunotherapy	2018	174

Page 1